4.10.15.2Vertical

Hematology & Blood Cancer Programs

Practices treating leukemia, lymphoma, and hematologic malignancies.

Market snapshot

These figures describe Oncology & Cancer Care (4.10.15), the segment that Hematology & Blood Cancer Programs sits within — not Hematology & Blood Cancer Programs on its own.

FragmentationConsolidatingEstimate

Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so oncology is not separately sized.

Business model & economics

Revenue model

Drug margin (buy-and-bill), services, and radiation

Key economics

Recurring revenue
Moderate–High

recurring treatment courses

EBITDA margin
Drug-margin- and site-of-care-driven
Capex intensity
Moderate

Characteristics

  • Consolidated around large community-oncology networks.
  • Drug margin and site-of-care economics are central.
  • Value-based oncology models emerging.

M&A deal context

Deal activityHigh

Who’s acquiring

  • Community-oncology networks
  • PE- and distributor-backed platforms
  • Value-based oncology acquirers

What’s driving deals

  • Consolidation around oncology networks.
  • Site-of-care and drug-margin economics.
  • Rising cancer incidence and novel therapies.

Find Hematology & Blood Cancer Programs acquisition targets

Search Acquisera’s index for companies classified under Hematology & Blood Cancer Programs (4.10.15.2) and build a targeted deal pipeline.

Search companies